China300896.CS▼
Imeik's first-half net profit plunges 24.84 percent as selling expenses surge 63 percent
Imeik released its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.216 billion yuan, down 6.42 percent year on year, and net profit attributable to shareholders of the listed company of 593 million yuan, down 24.84 percent year on year. Net cash flow from operating activities was 535 million yuan, down 18.32 percent year on year, and the weighted average return on equity fell to 7.62 percent from 10.10 percent in the same period last year. By product, solution-based injectable products generated revenue of 591 million yuan, down 20.51 percent year on year, gel-based injectable products generated 379 million yuan, down 23.08 percent, and freeze-dried powder injectable products generated 209 million yuan, surging 973.50 percent year on year. Selling expenses reached 235 million yuan, soaring 62.89 percent year on year, while administrative expenses rose 36.48 percent year on year. Rapidly expanding costs are eroding profit margins. Goodwill at the end of the period stood at 1.641 billion yuan, accounting for 17.88 percent of total assets. Of this, goodwill of 1.305 billion yuan was formed from the acquisition of South Korea's REGEN. If operations fall short of expectations, an impairment will be recognised. The company plans to distribute a cash dividend of 10 yuan, before tax, for every 10 shares to all shareholders.